1.34 mg/ml
Trade Name
Lugyda
Solution for injection in pre-filled pen
Request Type
New Registration
Drug Type
Biological
Approval Date
SFDA Approved Use
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
·as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
·in addition to other medicinal products for the treatment of diabetes.
·to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease
·to reduce the risk of sustained eGFR decline, kidney failure including initiation of chronic renal replacement therapy, or death from kidney failure or cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.
·as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
·in addition to other medicinal products for the treatment of diabetes.
·to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease
·to reduce the risk of sustained eGFR decline, kidney failure including initiation of chronic renal replacement therapy, or death from kidney failure or cardiovascular disease in adults with type 2 diabetes and chronic kidney disease.